Moneycontrol PRO
you are here: HomeNewsFavipiravir
favipiravir
Jump to
25 Results Found
  • Sun Pharma: Traction in speciality likely to sustain May 31, 2021 10:53 AM IST

    Sun Pharma: Traction in speciality likely to sustain

    Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well

  • Bal Pharma launches antiviral drug Favipiravir at Rs 85/tablet May 24, 2021 07:19 PM IST

    Bal Pharma launches antiviral drug Favipiravir at Rs 85/tablet

    Favipiravir is being used for patients with mild to moderate COVID-19 infection as it inhibits and terminates viral protein synthesis and induces lethal metagenesis of influenza virus.

  • Vivimed Labs gets DGHS nod to manufacture, market Favipiravir tablets in India May 10, 2021 12:57 PM IST

    Vivimed Labs gets DGHS nod to manufacture, market Favipiravir tablets in India

    Vivimed Labs in receipt of Government of India (DGHS) approval to manufacture and market Favipiravir tablets in the strengths of 200 mg and 400 mg under Vivimed’s own brand name ‘Favulous’ across India, the company said in a regulatory filing.

  • Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies? Apr 12, 2021 09:50 PM IST

    Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies?

    With the second Covid ‘Wave’ already surpassing the daily highs recorded in the month of September 2020 of about 95000, the demand for vaccines, critical medical equipment like vaccines, oxygen cylinders and ventilators have increased manifold. Watch the video to know what this evolving situation means for Indian Pharma?

  • Study shows Favipiravir provides multiple benefits in COVID-19 treatment: Glenmark Pharmaceuticals Nov 23, 2020 02:17 PM IST

    Study shows Favipiravir provides multiple benefits in COVID-19 treatment: Glenmark Pharmaceuticals

    Favipiravir is an antiviral medication that works by inhibiting a viral enzyme called RdRP (RNA dependent RNA polymerase), thereby halting the virus’s replication cycle. This helps control the multiplication of the virus and prevents its spread in the patient, Glenmark said.

  • Dr Reddy’s: Better US prospects to sustain valuations Oct 29, 2020 03:52 PM IST

    Dr Reddy’s: Better US prospects to sustain valuations

    Dr Reddy's US growth prospects have improved after its recent settlement with Bristol Myers Squibb to launch an oncology drug

  • SC seeks Centre's reply on plea alleging no approval for Remdesivir, Favipiravir to treat COVID-19 Oct 29, 2020 02:56 PM IST

    SC seeks Centre's reply on plea alleging no approval for Remdesivir, Favipiravir to treat COVID-19

    Advocate M L Sharma petitioner in-person referred to the bench, also comprising Justices A S Bopanna and V Ramasubramanian, the World Health Organization (WHO) report of October 15 and said that nowhere these medicines are designated officially as medicines for coronavirus.

  • FDC launches 2 variants of Favipiravir in India at Rs 55 per tablet Aug 25, 2020 07:45 PM IST

    FDC launches 2 variants of Favipiravir in India at Rs 55 per tablet

    The Drug Controller General of India (DCGI) had earlier approved the use of Favipiravir, an off patent, oral antiviral drug that has been shown to quicken clinical recovery in COVID-19 patients with mild to moderate symptoms, FDC said in a statement.

  • Prospects for US business and leadership in respiratory therapies make Cipla attractive Aug 10, 2020 08:15 AM IST

    Prospects for US business and leadership in respiratory therapies make Cipla attractive

    Cipla's US revenues clocked a sequential improvement to about $135 million, backed by a ramp-up in the generic version of gProventil HFA

  • Zenara Pharma receives DCGI approval to manufacture, sell Favipiravir tablets Aug 05, 2020 05:10 PM IST

    Zenara Pharma receives DCGI approval to manufacture, sell Favipiravir tablets

    The tablet, which will be sold under the brand name 'Favizen', is being manufactured at Zenar's US FDA approved facility here, a press release from the drug maker said.

  • COVID-19 treatment | BDR Pharmaceuticals launches Favipiravir at Rs 63 per tablet in India Aug 05, 2020 03:00 PM IST

    COVID-19 treatment | BDR Pharmaceuticals launches Favipiravir at Rs 63 per tablet in India

    The company has also come up with a patient assistance programme which will allow patients and institutions who have limited resources to purchase the medicine at a highly subsidised rate, BDR Pharmaceuticals said in a statement.

  • Lupin launches COVID-19 drug Favipiravir in India at Rs 49 per tablet Aug 05, 2020 12:55 PM IST

    Lupin launches COVID-19 drug Favipiravir in India at Rs 49 per tablet

    Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.

  • India's Hetero Labs wins approval to launch COVID-19 drug favipiravir Jul 29, 2020 12:10 PM IST

    India's Hetero Labs wins approval to launch COVID-19 drug favipiravir

    The drug, priced at 59 rupees (79 cents) per tablet, will be available at drug stores from Wednesday, privately held Hetero said.

  • Avra Laboratories gets CDSCO nod to make Favipiravir API Jul 27, 2020 08:15 PM IST

    Avra Laboratories gets CDSCO nod to make Favipiravir API

    The company, in a press release, said it has developed an alternative low cost and highly efficient manufacturing process and is now supplying commercial quantities to drug maker Cipla for the launch of Ciplenza, the generic version of Favipiravir.

  • Coronavirus India | Cipla to soon launch COVID-19 drug Ciplenza at Rs 68 per tablet Jul 24, 2020 08:25 PM IST

    Coronavirus India | Cipla to soon launch COVID-19 drug Ciplenza at Rs 68 per tablet

    Favipiravir, which is known to quicken the pace of clinical recovery of COVID-19 patients, is an oral anti-viral drug under the brand name Ciplenza

  • Brinton Pharma gets DCGI nod to market Favipiravir for treatment of COVID-19 patients Jul 23, 2020 07:41 PM IST

    Brinton Pharma gets DCGI nod to market Favipiravir for treatment of COVID-19 patients

    To be available in 200 mg tablets, the drug will be sold at a maximum retail price of Rs 59 per tablet, Brinton Pharmaceuticals said in a statement.

  • Coronavirus treatment | FabiFlu much more affordable than other options: Glenmark tells DCGI Jul 21, 2020 10:30 AM IST

    Coronavirus treatment | FabiFlu much more affordable than other options: Glenmark tells DCGI

    On July 13, Glenmark Pharmaceuticals cut the price of its antiviral drug Favipiravir, under the brand name FabiFlu, by 27 percent to Rs 75 per tablet.

  • DCGI seeks clarification from Glenmark Pharma on its claim of FabiFlu use for COVID-19 patients with comorbidities Jul 19, 2020 08:30 PM IST

    DCGI seeks clarification from Glenmark Pharma on its claim of FabiFlu use for COVID-19 patients with comorbidities

    Glenmark Pharmaceuticals had on July 13 said it has cut the price of its antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 by 27 percent to Rs 75 per tablet.

  • DCGI pulls up Glenmark for false claim on Favipiravir Jul 19, 2020 01:33 PM IST

    DCGI pulls up Glenmark for false claim on Favipiravir

    DCGI issued notices based on a representation by a Member of Parliament (MP), who complained about the cost of the drug and the false claims.

  • Biophore India gets DCGI nod to manufacture COVID-19 drug Favipiravir Jul 14, 2020 01:45 PM IST

    Biophore India gets DCGI nod to manufacture COVID-19 drug Favipiravir

    Besides DCGI's nod to produce the active pharmaceutical ingredient in India, it has been cleared for exports as well.

  • Maharashtra govt to procure large supplies of Remdesivir, Favipiravir Jun 26, 2020 07:40 AM IST

    Maharashtra govt to procure large supplies of Remdesivir, Favipiravir

    "We have decided to buy Remdesivir and Favipiravir as well as other essential drugs to treat COVID-19 patients in large numbers. The drugs are costly so the state has decided to buy them itself," he told reporters here.

  • Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID fight, say medical experts Jun 22, 2020 08:27 PM IST

    Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID fight, say medical experts

    Dr Avi Kumar, Consultant, Pulmonologist, Fortis Escort Heart Institute, said drugs such as Favipiravir and Remdisiver "cannot be called game changers" as they are used as a supportive treatment.

  • COVID-19 treatment | Indian companies begin exports of Favipiravir, but wait for approval in India Jun 19, 2020 03:36 PM IST

    COVID-19 treatment | Indian companies begin exports of Favipiravir, but wait for approval in India

    Sources told Moneycontrol that Glenmark's Favipiravir is expected to get approval from drug regulator any moment, based on the intermediate data from the clinical trials given the urgency of the situation

  • Coronavirus pandemic: From plasma therapy to Favipiravir, here's a list of treatments and antidotes for COVID-19 so far May 13, 2020 07:26 PM IST

    Coronavirus pandemic: From plasma therapy to Favipiravir, here's a list of treatments and antidotes for COVID-19 so far

    The science and technology ministry has reportedly earmarked 42 existing drugs, narrowed down from a list of at least 2,100 approved drugs, for repurposing.

  • Laurus Labs Q4: Improving product mix and strong execution drive growth May 05, 2020 09:29 AM IST

    Laurus Labs Q4: Improving product mix and strong execution drive growth

Sections
ISO 27001 - BSI Assurance Mark